En­livex’s shares cut in half af­ter ‘bi­as­es’ cloud Ph2 cell ther­a­py da­ta in sep­sis

En­livex Ther­a­peu­tics’ cell ther­a­py has dis­ap­point­ed in­vestors be­cause its im­pact in a mid-stage test in sep­sis was dif­fi­cult to fig­ure out. The com­pa­ny nonethe­less said its can­di­date could have po­ten­tial in sep­sis specif­i­cal­ly due to uri­nary tract in­fec­tion.

The Is­rael-based com­pa­ny is study­ing its off-the-shelf cell ther­a­py de­signed to re­store macrophage home­osta­sis. In sep­sis, macrophages are re­pro­grammed out of their home­o­sta­t­ic state, con­tribut­ing to dis­ease sever­i­ty, En­livex said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.